Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Takeda Pharmaceutical Company Limited

Nektar Therapeutics

Baxter Aktiengesellschaft

Alfred Weber

Hans-Peter Schwarz

Wolfgang Teschner

Sonja Svatos

Azra Pljevljakovic

Ruth Madlener

Peter Turecek

Andrea Engelmaier

Harald Arno Butterweck

Theresa Friederike Bauer

Lucia Gnauer

Hanspeter Rottensteiner

Katalin Varadi

Juergen Siekmann

Peter Matthiessen

Herbert Gritsch

Dirk Voelkel

Heinz Anderle

Susanne Vejda

Robert Pachlinger

Johann J Eibl

Zhihao Fang

Mary J Bossard

Yendra Linnau

Ping Zhang

Sean M Culbertson

Hans Peter Schwarz

Joris Hoefinghoff

Harold Zappe

Leopold Bruckschwaiger

Lucia Hofbauer

Wolfgang Sch&ouml;nhofer

Laura Lei

Gerald Schrenk

Jürgen Siekmann

Methods are provided for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-parvo B19 immunoglobulin G. The methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-parvo B19 immunoglobulin G are also provided. Methods for treating parvo B19 infections by administration of plasma-derived IgG compositions highly enriched for anti-parvo B19 immunoglobulin G are also provided.

Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS

Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.

Anti-factor IX padua antibodies

The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

Removal of serine proteases by treatment with finely divided silicon dioxide

Anti-factor IX Padua antibodies

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies), are also provided.

Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs

Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs

The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.

Method and compositions for specifically detecting physiologically acceptable polymer molecules

Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.

Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases

The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.

Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)

Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.

Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof

Growing community of inventors

Vienna, Austria

Alfred Weber